Liquidia Technologies Inc experienced a notable decline in its stock price as competition intensifies in the pulmonary arterial hypertension market.
Liquidia Technologies Inc (LQDA) saw its shares fall by 4.05% in yesterday's session, reflecting growing concerns over the competitive landscape for its key product, Yutrepia.
Advertisement
Liquidia Technologies Inc
LQDA.US
LQDA.US
Liquidia Technologies Inc
WealthAwesomeMarket cap
$6.33B
P/E
50.5x
52W high
$93.61
52W low
$21.35
1W change
+2.99%
Beta
0.54
Analyst Price Targets
Based on 10 analysts covering LQDA · as of Sep 17, 2026
Wall Street analysts forecast LQDA stock price to rise 52.4% over the next 12 months.
Consensus
Buy4.30 / 5.00
Avg. Target
C$107.75
+52.4% Upside
Current Price
C$70.69
Last close
Analyst Breakdown (10 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LQDA's historical volatility
30-Day Vol
48.7%
Annualized
90-Day Vol
60.2%
Annualized
Trend (90d)
-47.8%
Annualized drift
90d Mean
C$59.60
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$66.78 | C$56.46 – C$78.99 |
| 60 trading days | C$63.09 | C$49.75 – C$79.99 |
| 90 trading days | C$59.60 | C$44.56 – C$79.71 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should be cautious as Liquidia faces increasing competition from established players in the pulmonary arterial hypertension market, which could hinder its growth prospects.
4.05% decline in share price
Liquidia's stock has lost 9.1% over the past three months, underperforming against its industry, which saw a growth of 5.3%.
Bull case
Liquidia's unique PRINT technology and the strong launch of Yutrepia could set the stage for growth, especially if the company can effectively stand out in a crowded market.
Bear case
Intensifying competition from established therapies and new entrants poses a significant risk to Liquidia's market share and growth potential. Recent earnings estimates have also declined, raising further concerns.
Advertisement
Intensifying Competition in the PAH Market
Liquidia's Yutrepia, an inhaled dry-powder formulation of treprostinil, has quickly become a key growth driver since its launch. However, the company faces stiff competition from established players like United Therapeutics, which has a long-standing presence in the PAH market with its inhaled therapies. This competition could significantly impact Liquidia's ability to capture market share and sustain its growth.
Declining Earnings Estimates Raise Concerns
Recent revisions to earnings estimates have added to investor concerns. The Zacks Consensus Estimate for 2026 earnings per share has dropped from $3.02 to $2.57, signaling a potential slowdown in growth. With a Zacks Rank of #5 (Strong Sell), investors are advised to closely monitor Liquidia's performance and market positioning.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
